Profile of:

Carlos Gonzalez-Fernandez

Full name: Carlos Gonzalez-Fernandez

Current country: Spain

Membership level: Full

Type of membership: Member

Number of publications: 36

Long-Term Retention Rate of Golimumab in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis in a Real-Life Setting. (2022)

Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: A retrospective study. (2021)

Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review. (2020)

Patients’ perceptions on shared decision making during prescription of subcutaneous biological drug treatments for inflammatory arthritis: The RHEU‐LIFE survey (2020)

Patients’ perceptions on shared decision making during prescription of subcutaneous biological drug treatments for inflammatory arthritis: The RHEU‐LIFE survey (2020)

Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study. (2020)

Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. (2018)

Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology. (2018)

Assessment of SpondyloArthritis International Society (ASAS) Consensus on Spanish Nomenclature for Spondyloarthritis. (2018)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. (2018)

Recommendations for the Management of Comorbidity in Patients With Axial Spondyloarthritis in Clinical Practice. (2017)

Recommendations for the Use of Ultrasound and Magnetic Resonance in Patients With Spondyloarthritis, Including Psoriatic Arthritis, and Patients With Juvenile Idiopathic Arthritis. (2017)

Perceptions of patients with rheumatic diseases treated with subcutaneous biologicals on their level of information: RHEU-LIFE Survey. (2017)

Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products. (2017)

Budget Impact Analysis of Apremilast In Patients With Psoriatic Arthritis In Spain. (2015)

Cost-Utility Analysis of Apremilast for The Treatment of Psoriatic Arthritis Patients In Spain. (2015)

A deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk. (2015)

Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessment. (2015)

Two-year incidence of psoriasis, uveitis and inflammatory bowel disease in patients with spondyloarthritis: A study in the AQUILES cohort. (2015)

Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis. (2014)

Extra-articular disease in patients with spondyloarthritis. Baseline characteristics of the spondyloarthritis cohort of the AQUILES study. (2014)

PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. (2014)

Comparison of 2 referral strategies for the diagnosis of axial spondyloarthritis in Spain. The RADAR study. (2013)

High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). (2011)

Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis. (2011)

[Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients]. (2011)

Fibromyalgia in patients with ankylosing spondylitis: prevalence and utility of the measures of activity, function and radiological damage. (2010)

Relationship between spinal mobility and disease activity, function, quality of life and radiology. A cross-sectional Spanish registry of spondyloarthropathies (REGISPONSER). (2009)

Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. (2007)

[Actualización del Consenso de la Sociedad Española de Reumatología sobre el uso de antagonistas del TNFα en las espondiloartritis, incluida la artritis psoriásica]. (2007)

[Estudio 3(e)]. (2007)

Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study. (2005)

Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study. (2003)

Clinical significance of abdominal scintigraphy using 99mTc-HMPAO-labelled leucocytes in patients with seronegative spondyloarthropathies. (2000)

Abdominal scintigraphy using 99mTc-HMPAO-labelled leucocytes in patients with seronegative spondylarthropathies without clinical evidence of inflammatory bowel disease. (1996)

Different abdominal scintigraphy pattern in patients with ulcerative colitis, Crohn’s disease and seronegative spondylarthropathies. (1995)